Publications by authors named "Jorden L Welker"

T cell immunotherapy success is dependent on effective levels of antigen receptor expressed at the surface of engineered cells. Efforts to optimize surface expression in T cell receptor (TCR)-based therapeutic approaches include optimization of cellular engineering methods and coding sequences, and reducing the likelihood of exogenous TCR α and β chains mispairing with the endogenous TCR chains. Approaches to promote correct human TCR chain pairing include constant region mutations to create an additional disulfide bond between the two chains, full murinization of the constant region of the TCR α and β sequences, and a minimal set of murine mutations to the TCR α and β constant regions.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the efficacy of long-acting lenacapavir (LEN), an FDA-approved HIV capsid inhibitor, for pre-exposure prophylaxis (PrEP) using a simian model of HIV infection in pigtail macaques.
  • - Experimentation revealed that LEN demonstrated strong antiviral activity in vitro and maintained effective plasma levels in vivo, providing protection against HIV infection when administered before exposure.
  • - The results suggest that LEN could be a valuable option for PrEP in humans, reinforcing the relevance of the simian model in HIV research.
View Article and Find Full Text PDF

Background: Residual inflammation in people with HIV (PWH) despite suppression of HIV replication is associated with many comorbidities including cardiovascular disease. Targeting inflammation may decrease the risk of cardiovascular disease.

Methods: An open label randomized study was conducted to evaluate the effect of nine months of 81 mg aspirin versus 40 mg atorvastatin in antiretroviral therapy (ART) treated PWH and elite controllers (EC), not on ART.

View Article and Find Full Text PDF

In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent form where there is minimal transcription or protein expression. Latently infected cells are a major barrier to curing HIV. Increasing HIV transcription and viral production in latently infected cells could facilitate immune recognition and reduce the pool of infected cells that persist on ART.

View Article and Find Full Text PDF

In order to design effective strategies to eradicate the HIV, an understanding of persistent viral reservoirs is needed. Many studies have demonstrated HIV residual viremia prevalence in high income countries, data from low- and middle-income countries (LMIC) are limited. We assessed the prevalence, and factors associated with residual viremia in people with HIV (PWH), who were virally-suppressed on antiretroviral therapy (ART) in LMIC.

View Article and Find Full Text PDF